Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-07-22 | Reverse | 1:12 |
| 2025-02-21 | Reverse | 1:50 |
| 2024-06-05 | Reverse | 1:50 |
| 2022-11-29 | Reverse | 1:30 |
CNS Pharmaceuticals, Inc. develops anti-cancer drugs like Berubicin for brain tumors, with clinical trials and collaborations, based in Houston since 2017.
TPI 287 is a clinical-stage anti-cancer drug targeting aggressive brain tumors like glioblastoma, crossing the blood-brain barrier, and advancing to Phase 2 as CNS Pharmaceuticals' lead development program.
CNS Pharmaceuticals announced that three abstracts for its drug candidates, Berubicin and TPI 287, were accepted for poster presentations at the Society of Neuro-Oncology (SNO) 30th Annual Meeting. This news was met with significant investor optimism regarding the clinical progress of the company's pipeline for treating central nervous system cancers, leading to a notable increase in the company's stock price.
CNS Pharmaceuticals announced that John Climaco has stepped down as CEO and appointed Rami Levin, a biopharmaceutical executive with nearly 30 years of experience, as the new President and Chief Executive Officer, effective January 1, 2026. This move signals a strategic shift in leadership intended to guide the company through a pivotal period of advancing its clinical pipeline, particularly the TPI 287 program for brain cancers.
Shares of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP - Get Free Report) traded up 1.5% on Friday. The stock traded as high as $5.40 and last traded at $5.32. Approximately 10,901 shares changed hands during trading, an increase of 190% from the average daily volume of 3,759 shares. The stock had previously closed at $5.24. Analyst Ratings
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 KTTA | $0.47 | COMPARE |
 ENSC | $0.43 | COMPARE |
 SNGX | $0.37 | COMPARE |
 SXTP | $1.50 | COMPARE |
 GRI | $1.93 | COMPARE |
 SILO | $1.42 | COMPARE |
 CMND | $6.08 | COMPARE |
 WINT | $0.00 | COMPARE |
